NCT05213884View on ClinicalTrials.gov

The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2027

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Camrelizumab

200 mg, intravenous infusion over 30 minutes (Q3W); 1\~3 cycles of camrelizumab before radiotherapy and camrelizumab are maintained for 16 cycles (1 year) after the end of radiotherapy.

DRUG

Concurrent cisplatin chemotherapy

cisplatin is given at a dose of 40 mg/m2 via intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy every week for 6 cycles.

RADIATION

Intensity-modulated radiotherapy (IMRT)

70 Gy/ 35 fractions/7 weeks, 5 fractions/week, 1 fraction/day.

Trial Locations (3)

400030

RECRUITING

Chongqing University Cancer Hospital, Chongqing

404100

RECRUITING

Chongqing University Three Gorges Hospital, Wanzhou

646000

RECRUITING

The Affiliated Hospital of Southwest Medical University, Luzhou

All Listed Sponsors
lead

Chongqing University Cancer Hospital

OTHER